Here's What Analysts Are Forecasting For Prestige Consumer Healthcare Inc. (NYSE:PBH) After Its Third-Quarter Results
Here's What Analysts Are Forecasting For Prestige Consumer Healthcare Inc. (NYSE:PBH) After Its Third-Quarter Results
It's been a pretty great week for Prestige Consumer Healthcare Inc. (NYSE:PBH) shareholders, with its shares surging 11% to US$68.67 in the week since its latest third-quarter results. It was a credible result overall, with revenues of US$283m and statutory earnings per share of US$1.06 both in line with analyst estimates, showing that Prestige Consumer Healthcare is executing in line with expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
對於Prestige Consumer Healthcare Inc.(紐約證券交易所代碼:PBH)的股東來說,這是相當不錯的一週,自公佈最新的第三季度業績以來,其股價在本週飆升了11%,至68.67美元。總體而言,這是一個可信的業績,收入爲2.83億美元,法定每股收益爲1.06美元,均符合分析師的預期,這表明Prestige Consumer Healthcare的表現符合預期。對於投資者來說,這是一個重要時刻,因爲他們可以在報告中追蹤公司的業績,看看專家對明年的預測,看看對該業務的預期是否有任何變化。因此,我們收集了最新的業績後預測,以了解估計對明年的預測。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240211/0-a5377bbb2a0e45c7dfc8b12d7f66e7cd-0-218ce5fd02eed78a06bc16fa09699988.png/big)
Taking into account the latest results, the most recent consensus for Prestige Consumer Healthcare from seven analysts is for revenues of US$1.16b in 2025. If met, it would imply a credible 2.4% increase on its revenue over the past 12 months. Prestige Consumer Healthcare is also expected to turn profitable, with statutory earnings of US$4.63 per share. In the lead-up to this report, the analysts had been modelling revenues of US$1.16b and earnings per share (EPS) of US$4.60 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
考慮到最新業績,七位分析師對Prestige Consumer Healthcare的最新共識是,2025年的收入爲11.6億美元。如果得到滿足,這意味着其收入在過去12個月中可信地增長了2.4%。預計Prestige消費者醫療保健也將實現盈利,法定每股收益爲4.63美元。在本報告發布之前,分析師一直在模擬2025年收入爲11.6億美元,每股收益(EPS)爲4.60美元。因此,很明顯,儘管分析師已經更新了估計,但在最新業績公佈後,對該業務的預期沒有重大變化。
It will come as no surprise then, to learn that the consensus price target is largely unchanged at US$74.20. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. Currently, the most bullish analyst values Prestige Consumer Healthcare at US$84.00 per share, while the most bearish prices it at US$65.00. The narrow spread of estimates could suggest that the business' future is relatively easy to value, or thatthe analysts have a strong view on its prospects.
因此,得知共識目標股價基本保持不變爲74.20美元也就不足爲奇了。但是,這並不是我們可以從這些數據中得出的唯一結論,因爲一些投資者在評估分析師目標股價時也喜歡考慮估計值的差異。目前,最看漲的分析師對Prestige Consumer Healthcare的估值爲每股84.00美元,而最看跌的分析師估值爲每股65.00美元。估計值的狹窄差異可能表明該業務的未來相對容易估值,或者分析師對其前景有強烈的看法。
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Prestige Consumer Healthcare's past performance and to peers in the same industry. We would highlight that Prestige Consumer Healthcare's revenue growth is expected to slow, with the forecast 1.9% annualised growth rate until the end of 2025 being well below the historical 4.2% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 9.0% per year. Factoring in the forecast slowdown in growth, it seems obvious that Prestige Consumer Healthcare is also expected to grow slower than other industry participants.
這些估計很有趣,但是在查看預測與Prestige Consumer Healthcare過去的表現以及與同一行業的同行進行比較時,可以更粗略地描述一些細節。我們要強調的是,Prestige Consumer Healthcare的收入增長預計將放緩,預計到2025年底的年化增長率爲1.9%,遠低於過去五年4.2%的歷史年增長率。相比之下,該行業中其他有分析師覆蓋的公司的收入預計將以每年9.0%的速度增長。考慮到預期的增長放緩,很明顯,Prestige Consumer Healthcare的增長速度預計也將低於其他行業參與者。
The Bottom Line
底線
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
要了解的最重要的一點是,市場情緒沒有重大變化,分析師再次確認該業務的表現與他們先前的每股收益預期一致。從好的方面來看,收入估計沒有重大變化;儘管預測表明它們的表現將比整個行業差。共識目標股價沒有實際變化,這表明該業務的內在價值與最新估計相比沒有發生任何重大變化。
Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Prestige Consumer Healthcare going out to 2026, and you can see them free on our platform here..
考慮到這一點,我們仍然認爲該業務的長期發展軌跡對於投資者來說更爲重要。在Simply Wall St,我們有分析師對到2026年的Prestige Consumer Healthcare的全方位估計,你可以在我們的平台上免費查看。
However, before you get too enthused, we've discovered 1 warning sign for Prestige Consumer Healthcare that you should be aware of.
但是,在你變得過於熱情之前,我們已經發現了Prestige消費者醫療保健的1個警告信號,你應該注意這一點。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。